Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia

Arslan O., Ustun C., Arat M., Celebi H., Akan H., BEKSAÇ M., ...Daha Fazla

HEMATOLOGICAL ONCOLOGY, cilt.16, sa.4, ss.155-162, 1998 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 4
  • Basım Tarihi: 1998
  • Dergi Adı: HEMATOLOGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.155-162
  • Anahtar Kelimeler: allogeneic peripheral blood stem cell transplantation, acute non-lymphoblastic leukemia, graft versus host disease, VERSUS-HOST DISEASE, COLONY-STIMULATING FACTOR, BONE-MARROW TRANSPLANTATION, ACUTE MYELOID-LEUKEMIA, HEMATOLOGIC MALIGNANCIES, PROGENITOR CELLS, ALLO-PBPCT, GRAFT, DONORS, GVHD
  • Ankara Üniversitesi Adresli: Evet

Özet

Unmodified allogeneic peripheral blood stem cell transplantation (alloPBSCT) was performed in 20 consecutive acute non-lymphoblastic leukemia (ANLL) patients from their HLA-identical siblings. There were 11 males and 9 females. Median age was 34 years (range 17-43). Donors were primed with 25-15 mu g/kg/day s.c. granulocyte-colony stimulating factor (G-CSF, Neupogen, Roche). Conditioning regimen was Bu (16 mg/kg) + Cy (120 mg/kg) in 19 patients and high dose Ara-C (3 gr/m(2) twice daily for 3 days) for one patient who relapsed after bone marrow transplantation. Eighteen patients were in CR1. CsA + short-term MTX (n=19) or CsA alone (n=1) were used for graft versus host disease (GVHD) prophylaxis. The median number of apheresis procedures for each patient was 2 (2-4). A median of 6.5 (3.2-38.2) x 10(8)/kg MNC or 9.4 (2.2-12.4) x 10(6)/kg CD34+ cells were given. Median days to reach granulocyte of >0.5 x 10(9)/l and platelet of >50 x 10(9)/l were 12 (10-14) and 15 (11-35) respectively. Day 100 transplant-related mortality was 20 per cent (4/20). Grade 2 to 4 AGVHD was seen in 8 out of 17 (47%) evaluable patients. Severe AGVHD occurred in 3 out of 17 (18%). Clinical CGVHD of all grades developed in 12 out of 17 (70%) evaluable patients. The mean disease-free survival and overall survival were 17 (range: 8-33 months) and 18 months (range: 10-34 months), respectively. In conclusion, alloPBSCT in ANLL is associated with a faster engraftment, no greater incidence of AGVHD, but increased risk of CGVHD. Copyright (C) 1998 John Wiley & Sons, Ltd.